AI Article Synopsis

  • Brain metastasis from cervical cancer is rare and has a poor prognosis, with no established effective treatments known until recently.
  • A 50-year-old patient with cervical cancer developed multiple metastases and initially received various therapies, but with limited success.
  • After starting treatment with the PD-1/CTLA-4 inhibitor cadonilimab, the patient showed significant improvement, achieving a very good partial response and surviving over 18 months after the brain metastasis diagnosis.

Article Abstract

Background: Brain metastasis (BM) from cervical cancer (CC) is extremely rare. The prognosis of BM is poor. To our knowledge, no satisfactory therapeutic and standard effective treatments have been established. Immune checkpoint inhibitors (ICIs) treatment is emerging as a promising treatment in recurrence and metastasis(B/M) cervical cancer in recent years.

Case: We present a 50-year-old patient with CC who developed multiple metastasis (lung, brain and skin) 2 years after postoperative chemoradiotherapy. She received palliative therapy included chemotherapy, resection and stereotactic radiosurgery of BM with poor response. Then, the patient received second-line palliative monotherapy with a PD-1/CTLA-4 inhibitor(cadonilimab) and achieved clinical very good partial response (VGPR), a progression-free survival (PFS) of 14 months and overall survival of more than 18 months since BM.

Conclusion: We report a case of cervical cancer with multiple metastasis receiving cadonilimab and achieved considerable response and survival benefit.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513290PMC
http://dx.doi.org/10.3389/fimmu.2024.1434697DOI Listing

Publication Analysis

Top Keywords

cervical cancer
16
monotherapy pd-1/ctla-4
8
multiple metastasis
8
second-line monotherapy
4
pd-1/ctla-4 inhibitor
4
inhibitor effectively
4
effectively treated
4
treated multiple
4
multiple brain
4
brain lung
4

Similar Publications

Objective: The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee developed recommendations for the use of extended genotyping results in cervical cancer prevention programs.

Methods: Risks of cervical intraepithelial neoplasia grade 3 or worse were calculated using data obtained with the Onclarity HPV Assay from large cohorts. Management recommendations were based on clinical action thresholds developed for the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines.

View Article and Find Full Text PDF

Cytotoxic and antibacterial activity of naturally occurring agglutinin produced from the root of Poir.

Nat Prod Res

January 2025

Bioprocess Engineering Division, Smykon Biotech, Kanniyakumari, Tamilnadu, India.

Lectins are naturally occurring agglutinins which are produced more from plants sources compared to animal sources. The present study aims to screen the potential applications of lectin isolated from the mangrove plant, Poir. This root agglutinin of showed highest HA titre with buffalo erythrocytes.

View Article and Find Full Text PDF

Aim This study aimed to investigate women's knowledge and beliefs about cervical cancer and cervical smear examinations. Methodology The research was conducted at a health center in Greece from May 15, 2023, to August 15, 2023. The study sample consisted of 160 women aged 21-65 years who attended the health center.

View Article and Find Full Text PDF

Introduction Human papillomavirus (HPV) is the most common causative agent for cervical cancer (CC) in women. Despite extensive initiatives, the acceptance and implementation of vaccinations have remained inadequate, hindering a significant impact on public health outcomes. This study aimed to provide a comprehensive assessment of the knowledge, awareness, and practices (KAP) scores of medical and dental students regarding HPV infection and vaccination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!